🔎 Trials Near Me

Utama › Penyakit Autoimun › Wilayah Columbia › Washington

Kajian klinikal Penyakit Autoimun di Washington, DC

19 kajian untuk Penyakit Autoimun sedang mencari peserta di lokasi dalam dan sekitar Washington (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Mengambil pesertaFasa 1
  • MedStar Georgetown University Hospital, Washington D.C.
  • National Cancer Institute Developmental Therapeutics Clinic, Bethesda · 7 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT03816345

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT00867269

Natural History of Bronchiectasis

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 5 hingga 100 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT00943514

NIAID Centralized Sequencing Protocol

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • Children's National Health System, Washington D.C.
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
1 Day – 100 Years · Semua jantina · Dikemas kini 2 Okt 2026 · NCT03206099

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Mengambil pesertaFasa 2Sukarelawan sihat dialu-alukan
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 4 hingga 75 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT02579967

Environmental Risk Factors for the Anti-synthetase Syndrome

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 2 hingga 100 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT01276470

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Mengambil pesertaFasa 2
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 4 hingga 69 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT04339777

Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)

Mengambil pesertaFasa 1
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 18 hingga 70 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT04097561

Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

Mengambil pesertaKajian pemerhatian
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
1 Month – 100 Years · Semua jantina · Dikemas kini 24 Sep 2026 · NCT00246857

Study of Autoimmune Lymphoproliferative Syndrome (ALPS)

Mengambil pesertaKajian pemerhatian
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Sehingga umur 99 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT00001350

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Mengambil pesertaFasa 2
  • National Naval Medical Center, Bethesda · 7 mi jauh
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 18 hingga 90 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT00977977

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Mengambil pesertaFasa 3
  • Georgetown University Medical Center - Lombardi Comprehensive Cancer Center, Washington D.C.
  • American Oncology Partners of Maryland, PA, Bethesda · 7 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06722235

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Mengambil pesertaFasa 2/3
  • National Institutes of Health - Accepting Adult and Juvenile Patients, Bethesda · 7 mi jauh
Umur 6 hingga 75 · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06154252

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Mengambil pesertaFasa 3
  • Georgetown University Medical Center - Lombardi Comprehensive Cancer Center, Washington D.C.
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06948318

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Mengambil pesertaFasa 3
  • Site Number - 1024, Washington D.C.
Umur 18 hingga 80 · Semua jantina · Dikemas kini 30 Jul 2026 · NCT07039916

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Mengambil pesertaFasa 2
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 18 hingga 75 · Semua jantina · Dikemas kini 10 Jul 2026 · NCT05027945

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Mengambil pesertaKajian pemerhatian
  • Children's National Medical Center, Washington D.C.
  • Nih/Niaid, Bethesda · 7 mi jauh
  • Nih/Nhlbi, Bethesda · 7 mi jauh
Semua umur · Semua jantina · Dikemas kini 6 Jul 2026 · NCT01351545

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Mengambil pesertaFasa 2
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Umur 3 hingga 99 · Semua jantina · Dikemas kini 9 Mac 2026 · NCT04304820

X-linked Moesin Associated Immunodeficiency

Mengambil pesertaKajian pemerhatian
  • National Institutes of Health, Bethesda · 7 mi jauh
Umur 4 hingga 80 · Lelaki · Dikemas kini 25 Apr 2025 · NCT06278337

Kajian Penyakit Autoimun di bandar lain

Kajian lain di Washington

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.